Clinical Trials Directory

Trials / Completed

CompletedNCT03820024

MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback

The MOVES Trial: MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
39 (actual)
Sponsor
UNC Lineberger Comprehensive Cancer Center · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Overweight and obese endometrial cancer (EC) survivors at the University of North Carolina (UNC) at Chapel Hill will be approached for tailored feedback fitness intervention. The investigators plan to enroll 36 women (18 in each arm) to evaluate if receipt of weekly tailored feedback messages can improve physical activity in EC survivors. It is hypothesized that women receiving the feedback message intervention will increase step counts from baseline more than 2,000 steps compared to women in the non-intervention arm.

Detailed description

Objectives: * To assess if a tailored feedback fitness intervention can increase physical activity in EC survivors from baseline to 12 weeks post-baseline * To determine the acceptability of the fitness intervention in EC survivors through a completion survey. * To assess if a tailored feedback message fitness intervention can (1) decrease BMI, (2) reduce waitst to hip (W.H) ratios, (3) improve quality of life (QOL) and (4) improve serum metabolic markers (insulin, glucose and low density lipoprotein (LDL) in EC survivors.

Conditions

Interventions

TypeNameDescription
BEHAVIORALTailored Feedback MessagesParticipants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.

Timeline

Start date
2018-09-28
Primary completion
2019-12-23
Completion
2020-12-23
First posted
2019-01-29
Last updated
2021-07-29
Results posted
2021-07-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03820024. Inclusion in this directory is not an endorsement.